[go: up one dir, main page]

KEGG   DRUG: Nivolumab and relatlimab
Entry
D12334            Mixture   Drug                                   
Name
Nivolumab and relatlimab;
Nivolumab and relatlimab-rmbw;
Opdualag (TN)
Product
Component
Nivolumab [DR:D10316], Relatlimab [DR:D11350]
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
ATC code: L01FY02
Product: D12334<US>
Efficacy
Antineoplastic, Immune checkpoint inhibitor
  Disease
Melanoma [DS:H00038]
  Type
Monoclonal antibody, combination
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FY Combinations of monoclonal antibodies and antibody drug conjugates
     L01FY02 Nivolumab and relatlimab
      D12334  Nivolumab and relatlimab <US>
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12334  Nivolumab and relatlimab
Drug classes [BR:br08332]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12334  Nivolumab and relatlimab
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12334
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12334
Other DBs
PubChem: 497620747
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system